Cancer-associated fibroblasts: An emerging target of anti-cancer immunotherapy

540Citations
Citations of this article
712Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Among all the stromal cells that present in the tumor microenvironment, cancer-associated fibroblasts (CAFs) are one of the most abundant and critical components of the tumor mesenchyme, which not only provide physical support for tumor cells but also play a key role in promoting and retarding tumorigenesis in a context-dependent manner. CAFs have also been involved in the modulation of many components of the immune system, and recent studies have revealed their roles in immune evasion and poor responses to cancer immunotherapy. In this review, we describe our current understanding of the tumorigenic significance, origin, and heterogeneity of CAFs, as well as the roles of different CAFs subtypes in distinct immune cell types. More importantly, we highlight potential therapeutic strategies that target CAFs to unleash the immune system against the tumor.

Cite

CITATION STYLE

APA

Liu, T., Han, C., Wang, S., Fang, P., Ma, Z., Xu, L., & Yin, R. (2019, August 28). Cancer-associated fibroblasts: An emerging target of anti-cancer immunotherapy. Journal of Hematology and Oncology. BioMed Central Ltd. https://doi.org/10.1186/s13045-019-0770-1

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free